References
- Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry 1991; 36: 239–245
- Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 16: 1334–1349
- Lambert TJR, Chapman LH. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Med J Aust 2004; 181: 544–548
- Green A, Patel J, Goisman R. Weight gain from novel antipsychotic drugs: need for action. Gen Hosp Psychiatry 2000; 22: 224–235
- McElroy SL, Frye MA, Suppes T, et al. Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry 2002; 63: 207–213
- Wirshing DA. Schizophrenia and obesity: impact of antipsychotic medications. Acta Psychiatr Scand 2004; 65(Suppl 18)13–26
- Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709–2716
- McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005; 80: 19–32
- Fagiolini A, Frank E, Scott JA, Turkin S, Kupfer DJ. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord 2005; 7: 424–430
- De Hert M, van Winkel R, Van Eyck D, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 2006; 83: 87–93
- McIntyre RS, Konarski JZ, Wilkins K, Soczynska JK, Kennedy SH. Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being. Can J Psychiatry 2006; 51: 274–280
- Straker D, Correll CU, Kramer-Ginsberg E, et al. Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications. Am J Psychiatry 2005; 162: 1217–1221
- Le Fevre PD. Improving the physical health of patients with schizophrenia: therapeutic nihilism or realism?. Scott Med J 2001; 46: 11–31
- Ells LJ, Lang R, Shields JP, et al. Obesity and disability: a short review. Obes Rev 2006; 7: 341–345
- Allison DB, Mackell JA, McDonnell DD. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv 2003; 54: 565–567
- Von Korff M, Wayne K, Lin E, et al. Potentially modifiable factors associated with disability among people with diabetes. Psychosom Med 2005; 67: 233–240
- Ali S, Stone MA, Peters JL, Davies MJ, Khunti K. The prevalence of co-morbid depression in adults with Type 2 diabetes: a systematic review and meta-analysis. Diabet Med 2006; 23: 1165–1173
- Simon GE, von Korff M, Saunders K, et al. Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychiatry 2006; 63: 824–830
- Todaro JF, Shen BJ, Niaura R, Tilkemeier PL. Prevalence of depressive disorders in men and women enrolled in cardiac rehabilitation. J Cardiopulm Rehabil 2005; 25: 78–79
- American Diabetes Association. Consensus Development Conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27:596–601.
- International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Brussels: International Diabetes Federation, 2005. [Cited 20 March 2006.] Available from URL:, , http://www.idf.org/webdata/IDF_metasyndrome_definiton.pdf.
- Cameron AJ, Wellborn TA, Zimmet PZ, et al. Overweight and obesity in Australia: the 1999–2000 Australian Diabetes, Obesity and Lifestyle study (AusDiab). Med J Aust 2003; 178: 427–432
- Zimmet PZ, George K, Alberti MM, Shaw JE. Mainstreaming the metabolic syndrome: a definitive definition. Med J Aust 2005; 183: 175–176
- Lamberti JS, Olson D, Crilly JF, et al. Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry 2006; 163: 1273–1276
- Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001; 62: 22–31
- Correll CU, Frederickson AM., Kane JM, Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome?. Schizophr Res 2007; 89: 91–100
- Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001; 345: 790–797
- Nasrallah HA, Meyer JM, Goff DC, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006; 86: 15–22
- Newcomer JW. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psychiatry 2004; 65(Suppl 18)36–46
- Paton C, Esop R, Young C, Taylor D. Obesity, dyslipidemias and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatr Scand 2004; 110: 299–305